Rabbit anti-thymocyte globulin

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

TreatmentSickle Cell DiseaseAML, ChildhoodKidney Transplant Rejection

350 competitors in Treatment

#DrugCompanyPhaseTrials

1

Biltricide

Bayer

Preclinical

42

Minipress

Pfizer

Preclinical

13

Theo-Dur

Pfizer

Preclinical

14

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

65

Valium

Akero Therapeutics

Preclinical

26

Intuniv

PPromius Pharma, LLC

Preclinical

17

Clomid

Ferring

Preclinical

18

Aurlumyn

BBTG International Inc.

Preclinical

19

Rabbit anti-thymocyte globulin

Sanofi

Phase 1

110

Somavert

PPharmacia and Upjohn

Preclinical

1Show 30 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Severe Aplastic Anemia3 trials

Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

Completed·MMichael Pulsipher·N/A·NCT02845596·40 enrolled

Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia

Completed·Novartis·Phase 2·NCT04328727·36 enrolled

A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation With Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Active, not recruiting·BBoston Children's Hospital·Phase 3·NCT05600426·53 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT00448357·54 enrolled

Immunosuppression1 trial

Phase I/II Thymus Transplantation With Immunosuppression #950

Completed·SSumitomo Pharma Switzerland GmbH·Phase 1/2·NCT00579527·14 enrolled

Sickle Cell Disease1 trial

A Blood Stem Cell Transplant for Sickle Cell Disease

Active, not recruiting·—·Phase 1·NCT03249831·3 enrolled

Stem Cell Transplant1 trial

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00230035

10 more indications

Treatment1 trial

Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.

Active, not recruiting·VVastra Gotaland Region·N/A·NCT02936505·249 enrolled

Toxicity1 trial

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

Completed·UUniversity of Louisville·Phase 1·NCT02472392·10 enrolled

Transplantation1 trial

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Completed·SStanford University·Phase 2·NCT00899847·9 enrolled

Renal Transplant Recipients1 trial

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

Completed·Astellas·Phase 4·NCT00113269·501 enrolled

Allogeneic Stem Cell Transplantation1 trial

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

Completed·—·Phase 2/3·NCT01019876·38 enrolled

Lymphoid1 trial

Allogeneic Hematopoietic Cell Transplantation for Patients With Non-Malignant Disorders Using Treosulfan, Fludarabine, and Thiotepa

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT03980769·40 enrolled

Renal Transplant Failure and Rejection1 trial

Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression With Tacrolimus, Mycophenolic Acid and Corticosteroids

Recruiting·NNefro Avillion Clinical Development, LLC·Phase 2·NCT07508787·120 enrolled

AML, Childhood1 trial

A Phase I/II Pilot Study of Memory-like NK Cells to Consolidate TCRαβ T Cell Depleted Haploidentical Transplant in High-risk AML

Recruiting·WWashington University School of Medicine·Preclinical·NCT06158828·68 enrolled

Kidney Transplant Rejection1 trial

A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients

Recruiting·Sanofi·Preclinical·NCT07412470·526 enrolled

Unspecified1 trial

Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy

Unknown status·MMedical University of Silesia·N/A·NCT05199103·20 enrolled

Details

Drug Info

Related News